SCHEMBL4834010

SCHEMBL4834010

COP(=O)(Cc1ccc(NC(=O)/C=C/c2cnn(C)c2-c2ccccc2)cc1)OC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 4/20 0.45
CDK8 P49336 4/20 0.45
HDAC1 Q13547 6/20 0.43
HDAC2 Q92769 6/20 0.43
MEN1 O00255 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
RAB9A P51151 2/20 0.41
ACHE P22303 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
EGFR P00533 1/20 0.39
MMP1 P03956 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
BCHE P06276 1/20 0.39
ROCK1 Q13464 1/20 0.39
PKM P14618 1/20 0.39
NPC1 O15118 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834038 0.91 HDAC1 (0.44) CCNCCDK8HDAC1HDAC2MEN1
SCHEMBL4829232 0.91 HDAC1 (0.48) HDAC1HDAC2MEN1MAPTKMT2A
SCHEMBL4833889 0.91 CCNC (0.42) CCNCCDK8HDAC1HDAC2KMT2A
SCHEMBL4829174 0.91 CCNC (0.43) CCNCCDK8HDAC1HDAC2MEN1
SCHEMBL4829342 0.91 HDAC1 (0.48) HDAC1HDAC2MEN1MAPTKMT2A
SCHEMBL4834616 0.91 HDAC1 (0.45) CCNCCDK8HDAC1HDAC2MEN1
SCHEMBL4834311 0.91 HDAC1 (0.45) CCNCCDK8HDAC1HDAC2MEN1
SCHEMBL4833850 0.89 KMT2A (0.42) CCNCCDK8HDAC1HDAC2MEN1
SCHEMBL4827070 0.89 NPC1 (0.42) CCNCCDK8MAPTKMT2ARAB9A
SCHEMBL4827118 0.89 CCNC (0.47) CCNCCDK8HDAC1HDAC2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885HDAC1 662/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 CCNC 2548/4885CDK8 2963/4885HDAC1 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.